WallStSmart

Cytokinetics Inc (CYTK)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cytokinetics Inc generates 11765% more annual revenue ($88.04M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).

CYTK

Avoid

24

out of 100

Grade: F

Growth: 3.3Profit: 2.5Value: 4.0Quality: 5.8
Piotroski: 5/9Altman Z: -3.69

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 7.3
Piotroski: 2/9Altman Z: 3.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CYTKSignificantly Overvalued (-18.2%)

Margin of Safety

-18.2%

Fair Value

$56.52

Current Price

$76.91

$20.39 premium

UndervaluedFair: $56.52Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CYTK0 strengths · Avg: 0/10

No standout strengths identified

RVMD1 strengths · Avg: 10.0/10
Altman Z-ScoreHealth
3.2710/10

Safe zone — low bankruptcy risk

Areas to Watch

CYTK4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-572.0%2/10

ROE of -572.0% — below average capital efficiency

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
17.1x4/10

Trading at 17.1x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : CYTK

CYTK has a balanced fundamental profile.

Bull Case : RVMD

The strongest argument for RVMD centers on Altman Z-Score.

Bear Case : CYTK

The primary concerns for CYTK are Revenue Growth, EPS Growth, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

CYTK is growing revenue faster at 4.9% — sustainability is the question.

CYTK generates stronger free cash flow (-151M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CYTK scores higher overall (24/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cytokinetics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is headquartered in South San Francisco, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?